Amisk

Amisk is a New York-based biotechnology company focused on the discovery and development of novel therapies for inflammatory and fibrotic diseases. The company was founded in 2022 by Dr. Michael Vincent, who previously served as the Senior Vice President and Chief Scientific Officer of Pfizer’s Inflammation & Immunology Research Unit. Amisk aims to address significant unmet medical needs in conditions where tissue scarring and chronic inflammation lead to organ failure, such as idiopathic pulmonary fibrosis and NASH. By leveraging advanced insights into immunological pathways, the company is building a pipeline of precision medicines designed to modify disease progression. Amisk operates as a private, venture-backed entity currently in the pre-clinical stage of development.